Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis

European Journal of Pediatrics

Volumn 172, Issue 1, 2013, Pages 91-98

  Bonyadi, M ^a,b   Shaghaghi, Z ^a,b   Haghi, M ^a   Dastgiri, S ^c  

^a UNIVERSITY OF TABRIZ   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Amyloidosis; Familial Mediterranean fever; Iranian Azeri Turks; Plasminogen activator inhibitor 1 4G 5G Polymorphism

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

AMYLOIDOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; ETHNIC GROUP; FAMILIAL MEDITERRANEAN FEVER; FEMALE; FEVER; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HOMOZYGOSITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PAI1 GENE; PLEURISY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK REDUCTION; TURKEY (REPUBLIC);

AMYLOIDOSIS; AZERBAIJAN; CASE-CONTROL STUDIES; CHILD; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; IRAN; MALE; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; TURKEY;

EID: 84872612126     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-012-1844-z     Document Type: Article

References (42)

1. Ariue Oh CKB, Alban RF, Shaw B, Cho SH (2002) PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 294:1155-1160
2. Bakkaloglu A (2003) Familial Mediterranean fever. Pediatr Nephrol 18:853-859
3. Balci B, Tinaztepe K, Yilmaz E, Gucer S, Ozen S, Topaloglu R, Besbas N, Ozguc M, Bakkaloglu A (2002) MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant 17:1921-1923
4. Ben-Chetrit E, Backenroth R (2001) Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis 60:146-149
5. Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P (2010) Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS One 5:e9136
6. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW (2002) Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 17:56-61
7. Bonyadi M, Esmaeili M, Karimi A, Dastgiri S (2010) Common Mediterranean fever gene mutations in the Azeri Turkish population of Iran. Genet Test Mol Biomarkers 14:149-51
8. Cazeneuve C, Sarkisian T, Pecheux C, Dervichianet M, Nedelec B, Reinert P, Ayvazyan A, Kouyoumdjian JC, Ajrapetyan H, Delpech M, Goossens M, Dodé C, Grateau G, Amselem S (1999) MEFV-gene analysis in Armenians patients with FMF: diagnostic value, unfavorable renal prognosis of the M694V homozygous genotype, genetic and therapeutic implications. Am J Hum Genet 65:88-97
9. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, O'Shea JJ, Rosenberg HF, Malech HL, Kastner DL (2000) The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95:3223-3231
10. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variation at the plasminogen activator-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11:183-90
11. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney A (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator-1 (PAI-1) gene respond differently to interleukin- 1 in HepG2 cells. J Biol Chem 268:10739-10745
12. Dellas C, Loskutof DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93:631-40
13. Demirel A, Celkan T, Kasapcopur O, Bilgen H, Ozkan A, Apak H, Arisoy N, Yildiz I (2008) Is familial Mediterranean fever a thrombotic disease or not? Eur J Pediatr 167:279-285
14. Eisenberg S, Aksentijevich I, Deng Z, Kastner D, Matzner Y (1998) Diagnosis of familial Mediterranean fever by a molecular genetics method. Ann Intern Med 129:539-42
15. Eriksson P, Kallin B, van t' Hooft FM, Bavenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92:1851-1855
16. Esmaeili M, Bonyadi M, Rafeey M, Sakha K, Somi MH (2008) Common MEFV mutation analysis in Iranian Azeri Turkish patients with familial Mediterranean fever. Semin Arthritis Rheum 37:334-338
17. Gershoni-Baruch R, Shinawi M, Leah K, Badarnah K, Brik R (2001) Familial Mediterranean fever: prevalence, penetrance and genetic drift. Eur J Hum Genet 9:634-637
18. Hermans PWM, Hazelzet JA (2005) Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clin Infect Dis 41:S453-8
19. Hoekstra T, Geleijinse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG (2003) 4G-4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 34:2822-2828
20. Isordia-Salas I, Leaños-Miranda A, Sainz IM, Reyes-Maldonado E, Borrayo-Sanchez G (2009) Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial in-farction in young patients. Rev Esp Cardiol 62(4):365-372
21. Kohler HP, Grant PJ (2000) Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792-801
22. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H (2002) Acute phase response in familial Mediterranean fever. Ann Rheum Dis 61:79-81
23. Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyturk M, Akar S, Tunca M, Hawkins PN (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45:746-750
24. Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65:318-324
25. Lima LM, Carvalho MDS, Neto CPF, Garcia JCF, Sousa MO (2011) PAI-1 4G/5G Polymorphism and plasma levels association in patients with coronary artery disease. Arq Bras Cardiol 97(6):462-467
26. Livneh A, Langevitz P, Zemer D (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879-1885
27. Madách K, Aladzsity I, Szilágyi A, Fust G, Gal J, Penzes I, Prohaszka Z (2010) 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Critical Care 14:R79
28. Manduz S, Katrancioglu N, Karahan O, Ozdemir O (2010) Association of the plasminogen activator inhibitor-1(PAI-1) gene 4G/5G promoter polymorphism in Buerger's disease. (Tromboangiitis obliterans). Health 2:454-457
29. Medlej-Hashim M, Delague V, Chouery E, Salem N, Rawashdeh M, Lefranc G, Loiselet J, Megarbane A (2004) Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 5:4
30. Meigs JB, Dupuis J, Liu C, Donnell CJ, Fox CS, Kathiresan S, Gabrie SB, Larson MG, Yang O, Herber AG, Wilson PWF, Feng D, Tofler GH, Cupples LA (2006) PAI-1 Gene 4G/5G Polymorphism and risk of type 2 diabetes in a population-based sample. Obesity 14:753-758
31. Ozel Demiralp DF, Ekim M, Akar N (2009) The effect of plasminogen activator inhibitor-1-675 4G/5G polymorphism on familial Mediterranean fever (FMF) disease. Clin Appl Thromb Hemost 15(4):443-7
32. Ozen S (2004) Renal amyloidosis in familial Mediterranean fever. Kidney International 65:1118-1127
33. Reiner AP, Schwartz SM, Frank MB, Longstreth WT, Hindorff LA, Teramura G, Rosendaal FR, Gaur LK, Psaty BM, Siscovick DS (2012) Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. American Heart Association 32:2580-2587
34. Roest M, van der Schouw YT, Banga JD, Tempelman MJ, Groot PG, Sixma JJ, Grobbee DE (2000) Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 101:67-70
35. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998-7002
36. Shohat M, Magal N, Shohat T, Chen X, Dagan T, Mimouni A, Danon Y, Lotan R, Ogur G, Sirin A, Schlezinger M, Halpern GJ, Schwabe A, Kastner D, Rotter JI, Fischel-Ghodsian N (1999) Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 7:287-292
37. Simpson AJ, Booth NA, Moore NR, Bennett B (1991) Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 44:139-143
38. Strandberg L, Lawrence D, Ny T (1988) The organization of the human-plasminogen-activator-inhibitor-1 gene: implications on the evolution of the serine-protease inhibitor family. Eur J Biochem 176:609-16
39. The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797-807
40. van Mourik JA, Lawrence DA, Loskutoff DJ (1984) Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 259:14914-21
41. Wong TY, Poon P, Szeto CC, Chan JC, Li PK (2000) Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int 57:632-638
42. Yepiskoposyan L, Harutyunyan A (2007) Population genetics of familial Mediterranean fever: a review. Eur J Hum Genet 15:911-916